一个关于三角神经疼痛药物治疗的最新情况
Joseph V Pergolizzi1, Jo Ann LeQuang1, Salah N El-Tallawy2,3
1NEMA Research, Pain management, Naples, FL, USA.
Expert review of neurotherapeutics
|June 13, 2024
概括
较新的药物和组合疗法对治疗三角神经疼痛 (TN) 是有前途的,因为它有可能减少与卡巴马西平等老药物相关的副作用. 需要进一步的研究,以建立这些新方法的强有力的临床证据.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三神经疼痛 (TN) 是一种罕见的神经病痛疾病.
- 目前的治疗方法,如卡巴马泽平和卡巴泽平,具有显著的不良影响.
- 正在探索用于TN管理的新型治疗策略.
研究的目的:
- 审查三角神经疼痛的新兴药理选择.
- 讨论第三代抗药,CGRP阻断剂,胺和大麻素的潜力.
- 评估这些药物作为单一疗法或辅助药物的证据.
主要方法:
- 最近研究的文献综述和临床实践观察.
- 讨论新药剂的拟议作用机制.
- 考虑组合治疗方法的考虑.
主要成果:
- 目前对于新型TN治疗方法存在有限的强有力的临床证据.
- 尽管有不同的病理,但正在考虑偏头痛特异性药物.
- 组合疗法可能允许减少传统药物的剂量.
结论:
- 新的抗药,CGRP阻断剂,胺和大麻素代表了TN的潜在未来治疗方法.
- 组合疗法是一种减轻已知药物的副作用的实用方法.
- 进一步高质量的临床试验对于验证疗效和安全至关重要.
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
488
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
488
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:18Drug Delivery: Enteral Route
417
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
417
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
409
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
409